Predictors of dronedarone plasma drug concentrations and effect on atrial fibrillation/atrial flutter recurrence: Analyses from the EURIDIS and ADONIS studies.
Munveer ThindDavid S McKindleyJames A ReiffelGerald V NaccarelliJohn StewartPeter R KoweyPublished in: Clinical cardiology (2022)
Significant reduction in AF/AFL recurrence was observed in patients treated with dronedarone versus placebo, regardless of dronedarone concentrations above or below the median value.